Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst’s Next-Generation Factor VIIa Product CB 813d
May 24, 2016 08:30 ET
|
Catalyst Biosciences, Inc.
- Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor VIIa CB 813d -- Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B “Inhibitor” Patients...